Israel’s Sight Diagnostics said on Wednesday it raised $71 million in private funding to expand sales of its finger-prick blood analyzer and support research and development. Koch Disruptive Technologies, Longliv Ventures, which is part of the CK Hutchison Group, and Israel’s OurCrowd participated in the round, which brings Sight’s total funding to more than $124 million.

Read more here.